
ATAI Stock Forecast & Price Target
ATAI Analyst Ratings
Bulls say
AtaiBeckley is a clinical-stage biopharmaceutical company that has a strong focus on developing rapid-acting and effective mental health treatments, including BPL-003, VLS-01, and EMP-01. The company's potential for success is further supported by its strong pipeline, with BPL-003 expected to begin Phase 3 studies in 2Q26 and topline data guided for early 2029. While the company faces challenges and risks, including regulatory and commercial hurdles, its differentiated psychedelic assets and potential for integration into existing mental health treatment infrastructure make it a strong investment opportunity with a positive outlook.
Bears say
AtaiBeckley is developing novel therapies for mental health disorders, which is a growing and underserved market. However, the company's pipeline is still in early stages of clinical development and its success is not guaranteed, making it a high-risk investment. Additionally, reimbursement and utilization of their treatments may be a challenge, especially as shorter treatment durations may be preferred by patients and providers.
This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.
ATAI Analyst Forecast & Price Prediction
Start investing in ATAI
Order type
Buy in
Order amount
Est. shares
0 shares